Evelo Biosciences, Inc.

OTCPK:EVLO Stock Report

Market Cap: US$18.0

Evelo Biosciences Dividends and Buybacks

Dividend criteria checks 0/6

Evelo Biosciences does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Buyback Yield

Total Shareholder Yieldn/a
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Analysis Article • Aug 18

Is Evelo Biosciences (NASDAQ:EVLO) Using Debt In A Risky Way?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Seeking Alpha • Aug 11

Evelo Biosciences GAAP EPS of -$0.40 beats by $0.03

Evelo Biosciences press release (NASDAQ:EVLO): Q2 GAAP EPS of -$0.40 beats by $0.03. As of June 30, 2022, cash and cash equivalents were $92.0M, as compared to cash and cash equivalents of $68.4M as of December 31, 2021.
Seeking Alpha • Jul 18

Marella Thorell is the new finance chief of Evelo Biosciences

Evelo Biosciences (NASDAQ:EVLO) appoints 25 years of finance and operations experienced Marella Thorell as CFO, effective September 1, 2022. Most recently she served as Chief Accounting Officer and previously as Head of Finance of Centessa Pharmaceuticals.
Seeking Alpha • Jun 06

Evelo Biosciences: Hope After Dilution?

Today, we put Evelo Biosciences in the spotlight for the first time. The company has several potential catalysts on the horizon. The company also recently executed a large direct offering and brought aboard some strategic advisors as well. A full investment analysis follows in the paragraphs below.
Analysis Article • Mar 21

Evelo Biosciences (NASDAQ:EVLO) Has Debt But No Earnings; Should You Worry?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Sep 25

Is Evelo Biosciences (NASDAQ:EVLO) Weighed On By Its Debt Load?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Mar 11

What Type Of Shareholders Make Up Evelo Biosciences, Inc.'s (NASDAQ:EVLO) Share Registry?

If you want to know who really controls Evelo Biosciences, Inc. ( NASDAQ:EVLO ), then you'll have to look at the makeup...
Analysis Article • Dec 15

Trade Alert: The Independent Chairman Of Evelo Biosciences, Inc. (NASDAQ:EVLO), David Epstein, Has Just Spent US$51k Buying 77% More Shares

Whilst it may not be a huge deal, we thought it was good to see that the Evelo Biosciences, Inc. ( NASDAQ:EVLO...
Analysis Article • Dec 11

Do Institutions Own Evelo Biosciences, Inc. (NASDAQ:EVLO) Shares?

A look at the shareholders of Evelo Biosciences, Inc. ( NASDAQ:EVLO ) can tell us which group is most powerful. Large...

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if EVLO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EVLO's dividend payments have been increasing.

Dividend Yield vs Market

Evelo Biosciences Dividend Yield vs Market
How does EVLO dividend yield compare to the market?
SegmentDividend Yield
Company (EVLO)n/a
Market Bottom 25% (US)1.3%
Market Top 25% (US)4.2%
Industry Average (Biotechs)2.3%
Analyst forecast (EVLO) (up to 3 years)n/a

Notable Dividend: Unable to evaluate EVLO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EVLO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate EVLO's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as EVLO has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 03:21
End of Day Share Price 2026/06/18 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Evelo Biosciences, Inc. is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew LuchiniBMO Capital Markets Equity Research
Gary NachmanBMO Capital Markets Equity Research
Clarence PowellBMO Capital Markets Equity Research